

## (19) United States

### (12) Patent Application Publication (10) Pub. No.: US 2021/0206714 A1 Ginty et al.

Jul. 8, 2021 (43) **Pub. Date:** 

#### (54) COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT

(71) Applicant: President and Fellows of Harvard College, Cambridge, MA (US)

(72) Inventors: David D. Ginty, Boston, MA (US); Lauren L. Orefice, Boston, MA (US); Jinbo Lee, Andover, MA (US)

(73) Assignee: President and Fellows of Harvard College, Cambridge, MA (US)

(21)Appl. No.: 17/056,069

(22)PCT Filed: May 22, 2019

PCT/US2019/033581 (86) PCT No.:

§ 371 (c)(1),

(2) Date: Nov. 17, 2020

#### Related U.S. Application Data

(60)Provisional application No. 62/823,360, filed on Mar. 25, 2019, provisional application No. 62/674,770, filed on May 22, 2018.

#### **Publication Classification**

(51) **Int. Cl.** 

C07C 229/48 (2006.01)A61P 25/04 (2006.01)A61P 25/02 (2006.01)


U.S. Cl.

CPC ..... C07C 229/48 (2013.01); A61P 25/02 (2018.01); A61P 25/04 (2018.01)

(57)**ABSTRACT** 

The present invention features novel peripherally-restricted isoguvacine analogs with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.

# Tactile PPI



Compound #5 (GTI) Vehicle (2 mg/kg)